McNeal

Gross appearanceappearance of Hyperplastic prostateprostate

Mcneal

20 65% 25% 10%70 50%

2-5 cc 2 5 cc, 2cc 0.5cc

(0.15mg/ml)

80 90%80 90%

(5-alpha reductase)

755 0-7 8-19 20-35 20 35

51

Q1Q1

0 1 2 3 4 5

Q22 0 1 2 3 4 5

Q3Q3

0 1 2 3 4 5

Q4

0 1 2 3 4 5

Q5

0 1 2 3 4 5

Q6 0 1 2 3 4 5

Q7 5Q7

0 1 2 3 45

(

0-7 8 198-1920-35 20 35

::::

Adapted from Nordling J et al. In Benign Prostatic Hyperplasia. Plymouth, United Kingdom: Health Publication, 2001:107-166.

Slide I.2

BPHBPHBPHBPH10

8

9.0 40 ml >40 ml

(n=458)

66.1

5.6

4 3.6

3.1

22.3

0(p

BPHBPHBPHBPH80

70 6671

66

(n=90)

60

50 47

40

30

%

20

10

0

Adapted from Sells H et al Br J Urol Int 2000;85:440-445.

Slide II.4

ICBPH guideline

Adapted from Fifth International Consultation 2001 on BPH. In Benign Prostatic Hyperplasia. Plymouth, United Kingdom: Health Publication, 2001:519-535.

Slide IV.3

Slide II.1

( D i T i T l i )-( eg. Doxazosin, Terazosin, Tamsulosin)

5 -Proscar (finasteride)Avodart (dutasteride)

doxazosin finasteride

PROSCAR, finasteride)(AUR)

x

BPHBPHbethanecholbethanechol BPHBPHbethanechol bethanechol

1. BPHbethanecholfinasteride blocker 3finasteride-blocker 3

2. on Foley

detrusor x

BPHBPHbethanecholbethanechol BPHBPHbethanechol bethanechol

3. DM1

4. DMAUR4. DMAUR

5. NBneurogenic bladderurinary retention on Foleyretention on Foley

x